A longer-lasting COVID vaccine? UCLA study points the way
FINDINGSResearchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have identified rare, naturally occurring T cells that are capable of targeting a protein found in SARS-CoV-2 and a range of other coronaviruses.The findings suggest that a component of this protein, called viral polymerase, could potentially be added to COVID-19 vaccines to create a longer-lasting immune response and increase protection against new variants of the virus.BACKGROUNDMost COVID-19 vaccines use part of the spike protein found on the surface of the virus to prompt the immune system to produce antibo...
Source: UCLA Newsroom: Health Sciences - December 10, 2021 Category: Universities & Medical Training Source Type: news
Preventing the next public health emergency: New evidence demonstrates need to address antimicrobial resistance
COVID-19 is not the first pandemic caused by a novel strain of a virus affecting the upper respiratory tract.Over the past 100 years, pandemics have been caused by novel forms of influenza and other coronaviruses, such as severe acute respiratory syndrome coronavirus (SARS) and Middle East Severe respiratory syndrome (MERS). Common complications of each of these infections include pneumonia which can lead to secondary bacterial infections requiring treatment with antibiotics. (Source: The Catalyst)
Source: The Catalyst - November 18, 2021 Category: Pharmaceuticals Authors: Jocelyn Ulrich Tags: Research and Development Antimicrobial Resistance Source Type: news
Scientists are working on vaccine that will combat ALL types of coronaviruses
Researchers in San Diego and Boston are working together to develop a vaccine that will be effective against all forms of the coronavirus, including COVID-19, SARS and MERS. (Source: the Mail online | Health)
Source: the Mail online | Health - October 25, 2021 Category: Consumer Health News Source Type: news
SAGE: Next Covid variant could kill one in three people
Research presented to the Scientific Advisory Group for Emergencies (SAGE) today warned a future strain could be as deadly as MERS - which kill 35 per cent of infected people - could be on the way. (Source: the Mail online | Health)
Source: the Mail online | Health - July 31, 2021 Category: Consumer Health News Source Type: news
Knowledge of infection prevention and control among healthcare workers and factors influencing compliance: a systematic review
Conclusion: Embracing a multifaceted approach towards improving IPC-intervention strategies is highly suggested. The goal being to improve compliance among HCWs with IPC measures is necessary. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 16, 2021 Category: Consumer Health News Source Type: news
Anthony Fauci, 100 Days Into the Biden Administration, Is Finally Getting to Do His Job
When Dr. Anthony Fauci arrived at 1600 Pennsylvania Ave. for his first White House press briefing under the new Biden Administration, he could see things would be different.
It was the day after the Inauguration, and President Joe Biden was eager to get the country’s COVID-19 response back on track. Five minutes before he addressed the public, Fauci spoke with the new President. “He said, ‘I want you to just go and tell the science, explain to people that if we make mistakes, we’re going to fix the mistakes and we’re not going to dwell on the mistakes. Let science be communicated to the public...
Source: TIME: Health - May 18, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
MERS DNA vaccine induces immunity, protects from virus challenge in preclinical model
(The Wistar Institute) A synthetic DNA vaccine candidate for Middle East respiratory syndrome coronavirus (MERS-CoV) developed at Wistar induced potent immune responses and afforded protective efficacy in non-human primate models when given intradermally in abbreviated, low-dose immunization regimen. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 22, 2021 Category: Biology Source Type: news
Exclusive: Inside the Facilities Making the World ’s Most Prevalent COVID-19 Vaccine
If you’ve been vaccinated for COVID-19, chances are pretty high that you’re benefiting from a product made by BioNTech. The German biotech company, co-founded by a husband-and-wife team of scientists, developed the vaccine that became not only the first to earn authorization in the U.S. for COVID-19 in December but also the first ever based on a new technology involving the genetic material mRNA.
In interviews in December and March, co-founders Ugur Sahin and Ozlem Tureci spoke about their whirlwind year and their partnership with U.S. pharmaceutical company Pfizer to test and manufacture the vaccine. Over thre...
Source: TIME: Health - April 19, 2021 Category: Consumer Health News Authors: Alice Park and Aryn Baker/Marburg, Germany Tags: Uncategorized COVID-19 Exclusive feature longform Magazine photography Source Type: news
Microbicidal actives with virucidal efficacy against SARS-CoV-2 and other beta- and alpha-coronaviruses and implications for future emerging coronaviruses and other enveloped viruses, Scientific reports
Mitigating the risk of acquiring coronaviruses including SARS-CoV-2 requires awareness of the survival of virus on high-touch environmental surfaces (HITES) and skin, and frequent use of targeted microbicides with demonstrated efficacy. The data on stability of infectious SARS-CoV-2 on surfaces and in suspension have been put into perspective, as these inform the need for hygiene. We evaluated the efficacies of formulated microbicidal actives against alpha- and beta-coronaviruses, including SARS-CoV-2. The coronaviruses SARS-CoV, SARS-CoV-2, human coronavirus 229E, murine hepatitis virus-1, or MERS-CoV were deposited on pr...
Source: Current Awareness Service for Health (CASH) - April 15, 2021 Category: Consumer Health News Source Type: news
Researchers Are Hatching a Low-Cost Covid-19 Vaccine
A new formulation entering clinical trials in Brazil, Mexico, Thailand and Vietnam could change how the world fights the pandemic. (Source: NYT Health)
Source: NYT Health - April 5, 2021 Category: Consumer Health News Authors: Carl Zimmer Tags: your-feed-science Clinical Trials Coronavirus (2019-nCoV) MERS (Middle East Respiratory Syndrome) Eggs Immune System Influenza Factories and Manufacturing Antibodies Drugs (Pharmaceuticals) Biology and Biochemistry Gates, Bill and Me Source Type: news
Potential COVID-19 treatment identified in UCLA-led lab study
This study identified a new potential therapy that could help the global fight against COVID-19 and support populations that have been disproportionately affected by this deadly disease.”Drugs are categorized as small molecules when their individual molecules are tiny enough that they can penetrate to where they are needed. The researchers screened 430 drugs from among the approximately 200,000 compounds in CNSI ’sMolecular Screening Shared Resource libraries. They identified 34 that demonstrated at least some ability to halt the coronavirus, and eight that did so at relatively lower doses, before zeroing in on berzo...
Source: UCLA Newsroom: Health Sciences - March 24, 2021 Category: Universities & Medical Training Source Type: news
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
Building on deep scientific knowledge gained from decades of experience with viruses such as MERS, SARS, influenza, HIV and Hepatitis C, biopharmaceutical companies have madeunprecedented progress in advancing treatments and vaccines to help fight COVID-19. At this time, three vaccines and several treatments have received emergency use authorizations (EUAs) from the U.S. Food and Drug Administration (FDA) with one treatment receiving FDA approval. Additional candidates under investigation have also shown promise. (Source: The Catalyst)
Source: The Catalyst - March 8, 2021 Category: Pharmaceuticals Tags: Vaccines Coronavirus Source Type: news
Association between chronic fatigue syndrome and suicidality among survivors of Middle East respiratory syndrome over a 2-year follow-up period - Ahn SH, Kim JL, Kim JR, Lee SH, Yim HW, Jeong H, Chae JH, Park HY, Lee JJ, Lee H.
Suicide is an important public health issue during the current pandemic of emerging infectious diseases (EIDs). In EIDs, various symptoms persist even after recovery, and chronic fatigue is among those that are commonly reported. The aim of this study was ... (Source: SafetyLit)
Source: SafetyLit - March 4, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
< a href= " /news-events/nih-research-matters/antibody-treatment-mers-coronavirus-safe-people " > Antibody treatment for MERS coronavirus safe in people < /a >
A combination of two monoclonal antibodies prevented and effectively treated Middle East Respiratory Syndrome (MERS) in mice. (Source: NIH Research Matters)
Source: NIH Research Matters - March 2, 2021 Category: Research Source Type: news
Monoclonal antibodies against MERS coronavirus show promise in Phase 1 NIH-sponsored trial
Antibodies were well tolerated and generally safe when administered simultaneously to healthy adults. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - February 23, 2021 Category: American Health Source Type: news
